HVEM/HIF-1α promoted proliferation and inhibited apoptosis of ovarian cancer cells under hypoxic microenvironment conditions

Liyan Duan††, Jie Tao††, Xiaqian Yang†, Lei Ye†, Yueqian Wu†, Qizhi He†, Yingchun Duan‡, Li Chen‡ and Jianlong Zhu†‡*

Abstract

Background: Our previous studies showed the expression of herpes virus entry mediator (HVEM) is high in ovarian cancer samples and correlated to the patient clinic pathological features. As we all know, the hypoxic environment is the main feature of tumor. In this work, we explored the role of HVEM in hypoxic ovarian cancer cells and its effects on HIF-1α, a transcription factor responding to hypoxia.

Methods: The expression of HVEM, HIF-1α and apoptosis-related genes was detected by qRT-PCR and western blot. The proliferation and apoptosis of the ovarian cancer cells were determined with the Cell Counting Kit-8 assay and AnnexinV-FITC/PI-stained flow cytometry assay, respectively.

Results: The expression of HVEM was positively correlated to that of HIF-1α. The expression of HVEM and HIF-1α under hypoxic conditions was higher than that under normoxic conditions, which suggested that the level of HVEM and HIF-1α correlates with prolonged periods of hypoxia in ovarian cancer. The overexpression of HVEM promoted cell proliferation and inhibited cell apoptosis under hypoxic condition. HVEM overexpression elevated the expression of HIF-1α and Bcl-2 (anti-apoptotic protein), and reduced the expression of Bax (pro-apoptotic protein). In addition, overexpression of HVEM activated the AKT/mTOR signaling. Moreover, knockdown of HVEM had the completely opposite effects.

Conclusion: These data indicated that HVEM signaling might promote HIF-1α activity via AKT/mTOR signaling pathway and thus to regulate tumor growth in ovarian cancer under the hypoxic conditions. Furthermore, these findings indicate that this molecular mechanism could represent a therapeutic target for ovarian cancer.

Keywords: HVEM, Ovarian cancer, HIF-1α, Hypoxic microenvironment
**Introduction**

Ovarian cancer is the most commonly diagnosed malignant gynecological tumor and the primary cause of tumor-related mortality for genital system. Total 238,700 new cases and 151,900 deaths in situ of ovary were estimated worldwide in 2012; they accounted for 3.6% of all estimated new cases and 4.3% of all estimated deaths among female [1]. In United States, total 22,240 new cases and 14,070 deaths of ovary in situ, accounting for 2.5% of all estimated new cases and 4.9% of all estimated deaths among female, were estimated in 2018 [2]. Ovarian cancer was commonly treated with surgery, chemotherapy, and radiotherapy, which can alleviate some symptoms. However, these treatments seriously affect the quality of patient life and the recurrence rate is still high. Moreover, although much effort has been expended in the diagnosis and therapy of ovarian cancer, the 5 year survival rate is < 40% in patients [3]. The poor prognoses of ovarian cancer patients are related to chemotherapy resistance and tumor metastasis [4]. In recent years, numerous preclinical studies and clinical trials have shown that the microenvironment of the tumor is crucial to the malignant biological characteristics of these tumors [5]. The main feature of the tumor microenvironment is tissue anoxia [6]. Therefore, new therapeutic strategies that considered the hypoxic microenvironment are of great significance for the therapy of ovarian cancer.

Hypoxia-inducible factor 1 (HIF-1), consisting of HIF-1α and HIF-1β, is a heterodimeric protein. The expression of transcription factor HIF-1α is induced by a hypoxic environment and is maintained at a high level under hypoxic conditions [7, 8]. HIF-1α alters the metabolism of tumor cells, causes the release of the proangiogenic factors vascular endothelial growth factor (VEGF), N-myc downstream regulated 1 (NDRG1) and Glucose transporter 1 (GLUT1), promotes cell proliferation and inhibits cell apoptosis. Therefore, cancer cells can adapt and tolerate a hypoxic environment and even proliferate infinitely [9–11]. HIF-1α can be used to predict tumor progression and the overexpression HIF-1α is correlated to poor survival in the clinical context [12]. Tumor cells also display stem-cell-like properties, allowing their infinite proliferation under hypoxic conditions [13]. A recent study demonstrated that adrenomedullin promoted tumor angiogenesis by up-regulating the level of VEGF and HIF-1α in ovarian cancer [14], which suggested the importance of HIF-1α in the treatment of ovarian cancer.

Herpes virus entry mediator (HVEM) regulates the cellular entrance of Herpes simplex virus, and is also known as tumor necrosis factor receptor super family member 14 [15]. A clinical study demonstrated that HVEM was closely related to tumor development and immune evasion, which implied that it might be a new prognostic marker and underlying target for human tumors [16]. In our previous finding, we showed that the expression of HVEM was significantly high in ovarian cancer tissues and was closely correlated to the clinical pathological features of the patient, including the clinical stage (FIGO2013), lymph-node metastasis and recurrence [17]. However, the overexpression of HVEM had no effects on the cell multiplication in normoxic ovarian cancer cells [18]. In this work, we investigated the role of HVEM in hypoxic ovarian cancer cells and the relationship between HVEM and HIF-1α by overexpressing and silencing HVEM. This study demonstrates the potential utility of HVEM in novel therapeutic strategies for ovarian cancer.

**Results**

**HVEM co-expressed with HIF-1α in patients with ovarian cancer**

In our previous study, HVEM was found highly expressed in the ovarian cancer tissues compared with normal tissues [18]. Moreover, HVEM was correlated to TNM stage, lymph node metastasis and recurrence in ovarian serous adenocarcinoma [17]. Here, we analyzed the expression correlation of HVEM and HIF-1α using the online analysis tool Gene Expression Profiling Interactive Analysis [19]. The expression of HVEM was positively associated with that of HIF-1α (Fig. 1a and b) (Pearson R = 0.16, P = 0.001; Spearman R = 0.2, P = 3.1e-05). Thus, hypoxic microenvironment might mediate the effects of HVEM in promoting the development of ovarian cancer.

**Hypoxia enhanced the expression of HIF-1α and HVEM**

The primary ovarian cancer cells were isolated from the ovarian cancer tissues and identified by immunofluorescence staining for pan-cytokeratin (CK) and calretinin (CR). Almost all ovarian cancer cells were CK-positive, and all cells were CR-negative (Fig. S1), indicating the isolated cells are truly ovarian cancer cells. To validate the function of HVEM in ovarian cancer under hypoxic microenvironment, OVCAR3 cells and primary ovarian cancer cells were cultured under hypoxic conditions, which mimicked a more realistic tumor environment, and the expression of HIF-1α and HVEM in the hypoxic ovarian cancer cells was detected by qRT-PCR and western blot. Hypoxia induced elevated mRNA (Fig. 2a, b, d and e) and protein ((Fig. 2c and f) expression of HIF-1α and HVEM. Moreover, both the expression of HIF-1α and HVEM was gradually increased over time. After hypoxia for 12 h in OVCAR3 cells and hypoxia for 24 h in primary cells, the expression of HIF-1α significantly enhanced. However, the expression of HVEM markedly increased after hypoxia for 24 h in both OVCAR3 cells...
and primary cells. Therefore, hypoxia for 24 h was used in the following study.

Identification of HVEM knockdown and overexpression efficiency
To explore the function of HVEM in ovarian cancer, OVCAR3 cells and primary ovarian cancer cells were transfected with a small interfering RNA targeting HVEM (siHVEM) or pCDNA-HVEM (HVEM) to interfere the expression of HVEM. The knockdown and overexpression efficiency was identified by qRT-PCR and western blot. OVCAR3 cells transfected with siHVEM had significantly decreased expression of HVEM ($P = 0.004$), while the cells transfected with HVEM had obviously increased expression of HVEM ($P = 0.000$) (Fig. 3a-c). The siHVEM and HVEM vector also had similar effects on HVEM expression in primary ovarian cancer cells (Fig. 3d-f). All these results suggest that the expression of HVEM in both OVCAR3 cells and primary ovarian cancer cells are effectively silenced or overexpressed.

Effects of HVEM on cell proliferation of hypoxic ovarian cancer cells
The cell proliferation was measured by CCK-8 assay. As shown in Fig. 4, the cell viability was higher in both
Fig. 3 HVEM expression in OVCAR3 cells (a-c) and primary ovarian cancer cells (d-f) transfected with siHVEM or HVEM vector by qRT-PCR and Western blot. *P < 0.05, **P < 0.001, n = 3

Fig. 4 Effects of HVEM on the proliferation of OVCAR3 cells (a) and primary ovarian cancer cells (b) under hypoxic conditions. *P < 0.05, **P < 0.001 vs. Normoxia group; *P < 0.05, ***P < 0.001 vs. Hypoxia group; n = 3
hypoxic OVCAR3 cells and hypoxic primary cells compared with that in normoxic OVCAR3 cells and primary cells. Knockdown of HVEM inhibited hypoxia-induced cell proliferation, while overexpression of HVEM promoted hypoxia-induced cell proliferation further.

Effects of HVEM on cell apoptosis of hypoxic ovarian cancer cells
The cell apoptosis was detected by AnnexinV-FITC/PI-stained flow cytometry assay. Hypoxia suppressed the cell apoptosis of OVCAR3 cells (Fig. 5a) and primary cells (Fig. 5b). Knockdown of HVEM promoted cell apoptosis in hypoxic OVCAR3 cells and primary cells; while overexpression of HVEM inhibited cell apoptosis in hypoxic OVCAR3 cells and primary cells further.

Effects of HVEM on the expression of apoptosis-related proteins in hypoxic ovarian cancer cells
To further explore the underlying mechanism of HVEM in hypoxic ovarian cancer cells, the expression of
HVEM, HIF-1α, Bcl-2 (anti-apoptotic protein) and Bax (pro-apoptotic protein) was determined by qRT-PCR and western blot. Knockdown of HVEM significantly reduced hypoxia-induced expression of HIF-1α in hypoxic OVCAR3 cells and primary ovarian cancer cells. As presented in Fig. 6, overexpression of HVEM markedly enhanced hypoxia-induced expression of HIF-1α in hypoxic OVCAR3 cells and primary ovarian cancer cells further. Moreover, knockdown of HVEM significantly decreased the expression of Bcl-2 and increased the expression of Bax in hypoxic OVCAR3 cells and primary ovarian cancer cells; while overexpression of HVEM had the opposite effects.

Role of AKT/mTOR signaling pathway in the effects of HVEM in hypoxic ovarian cancer cells

It has been demonstrated that AKT/mTOR signaling pathway play a vital role in the regulation of HIF-1α in ovarian cancer [20, 21]. To investigate whether AKT/mTOR signaling pathway mediated the regulatory role between HVEM and HIF-1α, the expression of AKT/mTOR signaling pathway related protein was determined after intervening expression of HVEM by western blot. Hypoxia induced activation of AKT and mTOR in OVCAR3 cells (Fig. 7a and b). Knockdown of HVEM markedly blocked the signaling of AKT and mTOR in OVCAR3 cells, while overexpression of HVEM significantly promoted the activation of AKT and mTOR in OVCAR3 cells further. The activation of AKT and mTOR was also induced in hypoxic primary ovarian cancer cells (Fig. 7c and d). Silence of HVEM downregulated the expression of the phosphorylated AKT and mTOR in primary ovarian cancer cells. The regulation was not statistically significant. However, notably, no statistically significant difference was found in the expression of phosphorylated AKT and mTOR between normoxia group and hypoxia+siHVEM group. Moreover, overexpression of HVEM significantly promoted the activation of AKT and mTOR in primary ovarian cancer cells further. All these findings indicated that AKT/mTOR signaling was implicated in the role of HVEM in hypoxic ovarian cancer.

Discussion

The incidence of ovarian cancer has a progressive increase from 1999 to 2015 with annual percent changes (APC) of 1.8% in Korean [22]. It is well known that a lack of sufficient oxygen is a major characteristic of tumors, and these hypoxic conditions promote the epithelial–mesenchymal transition and tumor metastasis [23–25]. Therefore, identifying and tracking the markers under more realistic hypoxic environment should provide more information about the mechanisms of proliferation, apoptosis, invasion, and metastasis for ovarian cancer.

HIF-1α has been reported to play an important role in the metabolism and metastasis of cancer cells [26]. The expression of HIF-1α is regulated by multiple factors and HIF-1α highly expressed in many kinds of cancers, correlating with the proliferation, invasion and metastasis. Its high expression is associated with a poor prognosis [6, 27]. Numerous drugs inhibiting the activity of HIF-1α had been identified as anti-cancer agents [28–30]. HVEM was first identified in 1996 when screening for genes that mediate the entry of Herpes simplex virus into Chinese hamster ovary-K1 cells [15]. HVEM is the first member of the TNFR superfamily and expressed highly in many tissues, especially in those rich in lymphocytes, such as the spleen and lymph nodes. Our previous study found that HVEM expressed highly in ovarian cancer samples and associated with the patient clinicopathological features, including TNM staging, lymph node metastasis and recurrence [17]. In this study, the expression of HVEM was found positively correlated to that of HIF-1α in ovarian cancer. Therefore, we speculated that HVEM might exert its effects in the development of ovarian cancer via regulation of HIF-1α expression.

Moreover, in the present study, the expression of HIF-1α was gradually increased in hypoxic ovarian cancer cells when exposed to prolonged hypoxia. Notably, the expression of HVEM had the same trend as HIF-1α. Knockdown of HVEM markedly reduced the expression of HIF-1α; while overexpression of HEVM significantly increased the expression of HIF-1α. The results were consistent with the previous report that HVEM increased the activity of HIF-1α in vivo [31]. Additionally, exogenously expressing HVEM in primary ovarian cancer cells and OVCAR-3 cells markedly reduced the expression of Bax (pro-apoptotic protein) and significantly increased the expression of Bcl-2 (anti-apoptotic protein). However, knockdown of HVEM had the completely opposite impact. It has been reported that whether a cell lives or dies is mainly determined by the anti-apoptotic regulators Bcl-2 family and the apoptosis-promoting protein Bax [32]. When the expression of Bcl-2 exceeds that of BAX, cells do not undergo apoptosis. However, when the expression of Bax is dominant, cells are susceptible to apoptosis in response to inducers [33]. Therefore, inhibiting the expression of HVEM should suppress the proliferation of cancer cells. Our data also indicate that when the expression of HVEM was silenced, the cell apoptosis rate increased significantly.

AKT/mTOR signaling pathway has been known to play a vital role in the manipulation of HIF-1α in ovarian cancer [20, 21]. In the present study, knockdown of HVEM markedly blocked the activation of AKT and
Fig. 6 Effects of HVEM on the expression of HIF-1α and apoptosis-related protein in hypoxic OVCAR3 cells and hypoxic primary ovarian cancer cells. The mRNA (a) and protein (b) expression of HIF-1α and apoptosis-related protein in hypoxic OVCAR3 cells. The mRNA (c) and protein (d) expression of HIF-1α and apoptosis-related protein in hypoxic primary ovarian cancer cells. *P < 0.05, **P < 0.001 vs. Normoxia group; #P < 0.05, ##P < 0.001 vs. Hypoxia group; n = 3
mTOR, while overexpression of HVEM significantly promoted the signaling of AKT and mTOR in OVCAR3 cells and primary ovarian cancer cells further. Therefore, HVEM might regulate the expression level of HIF-1α via AKT/mTOR signaling pathway. However, the specific mechanism is still needed to be studied further.

In summary, the current study partially explained the relationship between the HVEM and HIF-1α under the hypoxic conditions. We observed that the HVEM promoted the expression of HIF-1α. To some extent, HVEM up-regulated the expression level of Bcl-2 and down-regulated that of Bax, which mediated the cancer cell apoptosis. Therefore, we assume that HVEM might lead to the development of ovarian cancer by regulating the expression of HIF-1α. These findings suggest a possible novel targeted therapeutic strategy for ovarian cancer. The effect of HVEM-HIF-1α axis in ovarian cancer is not fully elaborated. There are many works needed to do in the future work.

**Materials and methods**

**Isolation and identification of primary ovarian cancer cells and cells culture**

The experiments were approved by the Ethical Committee of Shanghai First Maternity and Infant Hospital, Tongji University School of Medicine and performed according to the Helsinki Declaration. The ovarian cancer tissues were obtained from Shanghai First Maternity and Infant Hospital, Tongji University School of Medicine. After surgery, small pieces of tumor tissue (0.3–0.8 cm) were placed in PBS containing penicillin and streptomycin and rotated for 1 h. After washing with PBS, the specimens were minced into 2 mm fragments and incubated with collagenase type II (800 u/ml; Sigma-Aldrich) at 37 °C for 30 min. Then, the cells were disaggregated.
by disruption and then filtered using a 100 μm cell strainer. We incubated the single primary ovarian cancer cells with anti-CD31- and anti-CD45-conjugated microbeads (Milenyi Biotec, Auburn, CA, USA) with 30 min of rotation at 4°C to remove the endothelial and hematopoietic cells. Then, the cells were collected and detected by immunofluorescence staining for pan-cytokeratin (CK) and calretinin (CR). The primary antibodies anti-pan-cytokeratin (sc-81,714, Santa Cruz Biotechnology, USA) and anti-calretinin (ab92341, Abcam, USA), and the secondary antibodies Alexa Fluor 488-labeled anti-rabbit IgG (A0423, Beyotime, JiangSu, China) and anti-mouse IgG (A0428, Beyotime, JiangSu, China) were applied. The nuclei were dyed with 4′, 6-diamidino-2-phenylinedole (DAPI, C1002, Beyotime, JiangSu, China).

OVCAR3 cells were bought from the Shanghai Institutes for Biological Sciences Cell Bank (Shanghai, China). The primary ovarian cancer cells and OVCAR3 cells were cultured in RPMI-1640 medium containing 1% antibiotics and 10% fetal bovine serum (Hyclone, Logan, UT, USA) in an incubator at 37 °C with 5% CO2 and 21% O2 (normoxia), or 5% CO2 and 1% O2 (hypoxia).

Quantitative real-time polymerase chain reaction (qRT-PCR)
The RNA was extracted with TRIzol method. The cDNA was synthesized using the Prime Script RT Reagent Kit (Takara, Kyoto, Japan). PCR reactions were performed in triplicate. The primer sequences were showed in Table 1. PCR was carried out at 95 °C for 10 min and then 10 s denaturation at 95 °C and 1 min annealing at 60 °C for 40 cycles. The mRNA level of the target genes was normalized to GAPDH using the 2−ΔΔCq method [34].

Western blot
The cells were placed in the radioimmune precipitation assay buffer and then the the cellular proteins were separated with SDS-15% polyacrylamide gel electrophoresis under denaturing conditions. Then, after blocked with 5% skim milk, the nitrocellulose membrane transferred with proteins were incubated with primary antibodies against HVEM (1:500; Ab62462, Abcam, USA), HIF-1 α (1:500; Ab113642, Abcam), Bcl-2 (1:400; Sc-492, Santa Cruz Biotechnology), Bax (1:300; Sc-493, Santa Cruz Biotechnology), AKT [1:1000; #9272, Cell Signaling Technology (CST)], p-AKT (1:1000; #9271, CST), mTOR (1:1000; #2972, CST), p-mTOR (1:1000; #2971; CST) and GAPDH antibodies (1:2000; #5174, CST, Danvers, MA, USA), followed by a horseradish-peroxidase-conjugated secondary antibody (Beyotime, Shanghai, China). The signals were determined by an enhanced chemiluminescence system (Bio-Rad). GAPDH was selected as the internal control.

Cell counting Kit-8 (CCK-8) assay
The cells were planted in 96-well plates (3 × 103 cells per well) and cultured overnight. After 0, 24, 48 or 72 h of incubation, 10% CCK-8 solution (100 μl) was added into each well. The optical density at 450 nm (OD450) was then detected with a microplate reader (Labsystems, Helsinki, Finland).

Cell apoptosis analyses
After 48 h of culture, the cells were collected and washed with PBS. Trypsin–EDTA solution was then sucked and added into the cell culture fluid with slight mixing. After 5 min of centrifugation, the upper supernatant was threw away and the cells were collected. We centrifuged 1 × 105 cells suspended in 1000 ml for 5 min, and discarded the supernatant. Then, the cells were stained with propidium iodide (20 μg/ml; Sigma-Aldrich) and RNase (100 μg/mL; Sigma-Aldrich) in the dark for 20 min at 4 °C. An AnnexinV-FITC/PI apoptosis detection kit (Beyotime, JiangSu, China) was performed to stain the cells. Cell apoptosis was then determined with a flow cytometer.

Statistical analysis
The data were presented as means ± standard deviations (SD) and analyzed with SPSS 22.0. The difference among groups was performed with one-way analysis of variance, followed by Tukey test. P < 0.05 was considered statistically significant.

| Table 1 Primer sequences for qRT-PCR |
|-------------------------------|-----------------|-----------------|-----------------|
| **Gene** | **NCBI accession number** | **Primer sequences (5′-3′)** | **Product length (bp)** |
| GADPH | NM_001256799.2 | F: AATCCCATCACCATCTTC | 218 |
| | | R: AGGCTGTGTCCTACTCTC | |
| HIF-1α | NM_001243084.1 | F: TTCCAGGCAATCAAAATA | 285 |
| | | R: ACTCAAAGGCAGACAGATAA | |
| HVEM | NM_001297605.1 | F: AACTGCTCCAGGACAGAGAA | 251 |
| | | R: ACGGAGACGATACCTTTGA | |
| Bcl2 | NM_000633.2 | F: TCCCTCGCTGCACAAATAC | 225 |
| | | R: TGGAAGGCCACATCTGAAC | |
| Bax | NM_001256799.2 | F: AATCCCATCACCATCTTC | 218 |

Duan et al. Journal of Ovarian Research (2020) 13:40; Page 9 of 11
Supplementary information
Supplementary information accompanies this paper at https://doi.org/10.1186/s13048-020-00646-3.

Additional file 1 Figure S1. Immunofluorescence staining for pan-cytokeratin (CK) and calretinin (CR) in the isolated primary ovarian cancer cells.

Abbreviations
HVEM: Herpes virus entry mediator; VEGF: Vascular endothelial growth factor

Acknowledgements
Not applicable.

Authors’ contributions
IZ and LD designed the study; LD and JT performed all the experiments and wrote the draft of the manuscript; XY, LY, YW, QH and YD collected the experimental materials and assisted the experiments; LC performed the bioinformatics analysis. All authors revised the manuscript.

Funding
This work was supported by Shanghai Pudong Hospital (grant No. YJRJ201805).

Availability of data and materials
The datasets used or analyzed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate
The experiments were approved by the Ethical Committee of Shanghai First Maternity and Infant Hospital, Tongji University School of Medicine and performed according to the Helsinki Declaration. Written informed consents were obtained from all patients.

Consent for publication
All patients agree with the publication.

Competing interests
The authors declare that they have no competing interests.

Received: 13 August 2019 Accepted: 7 April 2020

Published online: 20 April 2020

References
1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65:87–108.
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2018. CA Cancer J Clin. 2018;68:7–30.
3. Tomao F, Papa A, Rossi L, et al. Emerging role of cancer stem cells in the biology and treatment of ovarian cancer: basic knowledge and therapeutic possibilities for an innovative approach. J Exp Clin Cancer Res. 2013;32:48.
4. Mehn P, Puiseux A. Metastasis: a question of life or death. Nat Rev Cancer. 2006;6:449–58.
5. Hede K. Environmental protection: studies highlight importance of tumor microenvironment. J Natl Cancer Inst. 2004;96:1120–1.
6. Semenza GL. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene. 2010;29:625–34.
7. Sharp FR, Bernaudin M. HIF1 and oxygen sensing in the brain. Nat Rev Neurosci. 2004;5:437–48.
8. Majmundar AJ, Wong WJ, Simon MC. Hypoxia-inducible factors and the response to hypoxic stress. Mol Cell. 2010;40:294–309.
9. Nusrat O, Belotte J, Fletcher NM, et al. The role of angiogenesis in the persistence of Chemoresistance in epithelial ovarian cancer. Reprod Sci. 2016;23:1484–92.
10. Campbell EJ, Visser MC, Boznet S, Dyer A, Robinson BA, Dachs GU. Restoring physiological levels of ascorbate slows tumor growth and moderates HIF-1 pathway activity in Gulo(−/−) mice. Cancer Med. 2015;4:303–14.
11. Chen T, Ren Z, Ye LC, et al. Factor inhibiting HIF1alpha (FIH-1) functions as a tumor suppressor in human colorectal cancer by repressing HIF1alpha pathway. Cancer Biol Ther. 2015;16:244–52.
12. Daponte A, Ioannou M, Mylons I, et al. Prognostic significance of hypoxia-inducible factor 1 alpha (HIF-1 alpha) expression in serous ovarian cancer: an immunohistochemical study. BMC Cancer. 2008;8:335.
13. Marie-Egyptienne DT, Lohse J, Hill RP. Cancer stem cells, the epithelial to mesenchymal transition (EMT) and radioresistance: potential role of hypoxia. Cancer Lett. 2013;341:63–72.
14. Heckenberg KG, Costa SD, Gregory LM, Michael BF, Endris RG, Shoop WL. Comparison of thumb-counting and comb-counting methods to determine Ctenocephalides felis infestation levels on dogs. Vet Parasitol. 1994;53:153–7.
15. Montgomery RL, Warner MS, Lum BJ, Spear PG. Herpes simplex virus-1 entry into cells mediated by a novel member of the TENV/GNG receptor family. Cell. 1996;87:427–36.
16. Inoue T, Shi M, Yasuda S, et al. HVEM expression contributes to tumor progression and prognosis in human colorectal cancer. Anticancer Res. 2015;35:1361–7.
17. Fang Y, Ye L, Zhang T, He QZ, Zhu JL. High expression of herpesvirus entry mediator (HVEM) in ovarian serous adenocarcinoma tissue. J BUON. 2017;22:80–6.
18. Zhang T, Ye L, Han L, He Q, Zhu J. Knockdown of HVEM, a lymphocyte regulator gene, in ovarian Cancer cells increases sensitivity to activated T cells. Oncol Res. 2016;24:189–96.
19. Tang Z, Li C, Kang B, Gao G, Zhang Z. GEPIA: a web server for cancer and normal gene expression profiling and interactive visualization. Nucleic Acids Res. 2017;45:W98–W102.
20. Tamura K, Yoshie M, Miyajima E, Kano M, Tachikawa E. Stathmin regulates hypoxia-inducible factor-1alpha expression through the mammalian target of Rapamycin pathway in ovarian clear cell adenocarcinoma. ISRN Pharmacology. 2013;2013:279593.
21. Ataei-Kachooie P, Pourgholami MH, Bahrami BF, Badar S, Morris DL. Minocycline attenuates hypoxia-inducible factor-1alpha expression correlated with modulation of p53 and AKT/mTOR/p70S6K/4E-BP1 pathway in ovarian cancer: in vitro and in vivo studies. Am J Cancer Res. 2015;5:575–88.
22. Lim MC, Won YJ, Ko MJ, et al. Incidence of cervical, endometrial, and ovarian cancer in Korea during 1999-2015. J Gynecol Oncol. 2019;30:e38.
23. Chaturvedi P, Gilkes DM, Wong CC, et al. Hypoxia-inducible factor-1alpha modulates energy metabolism in cancer cells by inducing over-expression of specific glycolytic isoforms. Mini Rev Med Chem. 2009;9:1084–101.
24. Cheng JC, Klausen C, Leung PC. Hypoxia-inducible factor 1 alpha mediates epidermal growth factor-induced down-regulation of E-cadherin expression and cell invasion in human ovarian cancer cells. Cancer Lett. 2013;329:197–206.
25. Kizaka-Kondoh S, Inoue M, Harada H, Hiraoka M. Tumor hypoxia: a target for development of strategies to improve radiation therapy. Cancer Res. 2005;65:11113–22.
26. Kizaka-Kondoh S, Kondoh T, Morita S, Inoue M, Harada H, Hiraoka M. Tumor hypoxia: a target for development of strategies to improve radiation therapy. Cancer Res. 2005;65:11113–22.
27. Marin-Hernandez A, Gallardo-Perez JC, Ralph SJ, Rodriguez-Enriquez S, Moreno-Sanchez R. HIF-1alpha modulates energy metabolism in cancer cells by inducing over-expression of specific glycolytic isoforms. Mini Rev Med Chem. 2009;9:1084–101.
28. Mayerhofer M, Valent P, Grillitsch P, Sillaber C. BCR/ABL induces expression of vascular endothelial growth factor and its transcriptional activator, hypoxia inducible factor-1alpha, through a pathway involving phosphoinositide 3-kinase and the mammalian target of rapamycin. Blood. 2002;100:3767–75.
29. Luwor RB, Lu Y, Li X, Mendelsohn J. Antitumor effects of the epidermal growth factor receptor monoclonal antibody cetuximab/CI254 reduces hypoxia-inducible factor-1 alpha, leading to transcriptional inhibition of vascular endothelial growth factor expression. Oncogene. 2005;24:4433–41.
30. Pore N, Jiang Z, Gupta A, Cerniglia G, Kao GD, Matyja A. EGFR tyrosine kinase inhibitors decrease VEGF expression by both hypoxia-inducible factor (HIF)-1-independent and HIF-1-dependent mechanisms. Cancer Res. 2004;64:3197–204.
31. Sakoda Y, Anand S, Zhao Y, et al. Herpesvirus entry mediator regulates hypoxia-inducible-factor-1alpha and erythropoiesis in mice. J Clin Invest. 2011;121:4810–9.
32. Cory S, Huang DC, Adams JM. The Bcl-2 family: roles in cell survival and oncogenesis. Oncogene. 2003;22:658–607.
33. Rosse T, Olivier R, Monney L, et al. Bcl-2 prolongs cell survival after Bax-induced release of cytochrome c. Nature. 1998;391:496–9.
34. Ayuk SM, Abrahamse H, Houreld NN. The role of photobiomodulation on gene expression of cell adhesion molecules in diabetic wounded fibroblasts in vitro. J Photochem Photobiol B. 2016;161:368–74.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.